Research records indexed for Maridebart cafraglutide
This page carries 5 of the 13 records that the literature query returned for Maridebart cafraglutide, selected by citation count and preferring records that name the compound in their title. It is a selection, not a complete index, and the 8 records it does not carry are not represented here. Every row resolves to a real identifier and names the study model, so no finding reads as a human claim by default. The compound page is Maridebart cafraglutide.
Indexed records
| Record | Year | Study type | Model | n as stated | What it reported |
|---|---|---|---|---|---|
| Novel GLP-1-based Medications for Type 2 Diabetes and Obesity pmid:41054801 | 2026 | Review | other | Not stated | Indexed as review. compound named in the abstract, not the title. study model from MeSH "Animals" with no rodent species heading. subject headings: Diabetes Mellitus, Type 2; Obesity; Hypoglycemic Agents; Glucagon-Like Peptide 1; Glucagon-Like Peptides. |
| A metabolic comparison of GIPR agonism versus GIPR antagonism in male mice pmid:41287212 | 2026 | Comparative Study, research-article | rodent | Not stated | Indexed as comparative study, research-article. compound named in the abstract, not the title. study model from MeSH "Mice, Inbred C57bl". subject headings: Liver; Adipose Tissue; Mice, Inbred C57BL; Insulin Resistance; Obesity. |
| The Paradox and Future of GLP-1/GIP Combination Therapies: Efficacy and Mechanisms pmid:42166683 | 2026 | Review | other | Not stated | Indexed as review. compound named in the abstract, not the title. study model from MeSH "Animals" with no rodent species heading. subject headings: Obesity; Gastric Inhibitory Polypeptide; Receptors, Gastrointestinal Hormone; Anti-Obesity Agents; Drug Therapy, Combination. |
| Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity - A Phase 2 Trial pmid:40549887 | 2025 | Clinical Trial, Phase II, Multicenter Study | human trial | Not stated | Indexed as clinical trial, phase ii, multicenter study. study model from MeSH "Humans" with publication type "clinical trial, phase ii". subject headings: Diabetes Mellitus, Type 2; Obesity; Weight Loss; Receptors, Gastrointestinal Hormone; Anti-Obesity Agents. |
| A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings pmid:38316982 | 2024 | research-article, Clinical Trial, Phase I | human trial | Not stated | Indexed as research-article, clinical trial, phase i. compound named in the abstract, not the title. study model from MeSH "Humans" with publication type "clinical trial, phase i". subject headings: Obesity; Weight Loss; Peptides; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor. |
Where this page sits
Compound page: Maridebart cafraglutide. Class: Incretin receptor agonists.
Retrieved 2026-10-12.
Sources
- Drugs@FDA application register query for this compound, no application records returned. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:maritide
- Discovery of AMG 133, a Glucose-Dependent Insulinotropic Polypeptide Receptor Antagonist and Glucagon-Like Peptide 1 Receptor Agonist Antibody-Drug Conjugate for the Treatment of Obesity. Journal of medicinal chemistry (2026). pmid:41941715
- Design and therapeutic rationale of antibody-peptide conjugates: insights from maridebart cafraglutide (AMG133) and emerging applications. Antibody therapeutics (2026). pmid:42592044
- Phase I results for AMG 133. Nature reviews. Endocrinology (2024). pmid:38388678
- Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity - A Phase 2 Trial. The New England journal of medicine (2025). pmid:40549887
- Once-Monthly Maridebart Cafraglutide in Obesity - A Phase 2 Trial. The New England journal of medicine (2025). pmid:41337722
- Once-Monthly Maridebart Cafraglutide in Obesity - A Phase 2 Trial. Reply. The New England journal of medicine (2025). pmid:41337724
On each stated value was matched to the record cited for it. That is record matching, not an appraisal of the research. Compiled and checked by: Peptide Monographs editorial desk. No qualified clinical reviewer.